12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Maribavir: Interim Phase II data

ViroPharma disclosed on its 1Q13 earnings call that interim data from 36 patients with asymptomatic CMV infection in a European Phase II trial showed that twice-daily oral maribavir led to undetectable plasma CMV DNA in 93% of patients (n=28) vs. 63% of patients receiving Valcyte valganciclovir (n=8). One patient receiving maribavir did not clear virus while...

Read the full 268 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >